Trial · NCT01599650
Adverse events688
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 688
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Ranibizumab 0.5mg | 3 | 180 | |
| other | Vertigo | Ear and labyrinth disorders | Ranibizumab 0.5mg + Laser | 1 | 183 | |
| other | Vertigo | Ear and labyrinth disorders | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | 2 | 63 | |
| other | Vertigo | Ear and labyrinth disorders | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | 0 | 25 | |
| other | Blepharitis (Fellow untreated eye) | Eye disorders | Ranibizumab 0.5mg | 2 | 180 | |
| other | Blepharitis (Fellow untreated eye) | Eye disorders | Ranibizumab 0.5mg + Laser | 11 | 183 | |
| other | Blepharitis (Fellow untreated eye) | Eye disorders | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | 0 | 63 | |
| other | Blepharitis (Fellow untreated eye) | Eye disorders | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | 0 | 25 | |
| other | Blepharitis (Study eye) | Eye disorders | Ranibizumab 0.5mg | 3 | 180 | |
| other | Blepharitis (Study eye) | Eye disorders | Ranibizumab 0.5mg + Laser | 11 | 183 | |
| other | Blepharitis (Study eye) | Eye disorders | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | 1 | 63 | |
| other | Blepharitis (Study eye) | Eye disorders | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | 0 | 25 | |
| other | Cataract (Fellow untreated eye) | Eye disorders | Ranibizumab 0.5mg | 3 | 180 | |
| other | Cataract (Fellow untreated eye) | Eye disorders | Ranibizumab 0.5mg + Laser | 6 | 183 | |
| other | Cataract (Fellow untreated eye) | Eye disorders | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | 0 | 63 | |
| other | Cataract (Fellow untreated eye) | Eye disorders | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | 0 | 25 | |
| other | Cataract (Study eye) | Eye disorders | Ranibizumab 0.5mg | 8 | 180 | |
| other | Cataract (Study eye) | Eye disorders | Ranibizumab 0.5mg + Laser | 3 | 183 | |
| other | Cataract (Study eye) | Eye disorders | Laser Monotherapy With Ranibizumab 0.5 mg From Month 6 | 1 | 63 | |
| other | Cataract (Study eye) | Eye disorders | Laser Monotherapy Without Ranibizumab 0.5 mg From Month 6 | 0 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01599650/events